Major corporate developments:
Ascentage Pharma (06855): Multiple clinical advancements will be presented at the 2026 American Society of Hematology (ASH) Annual Meeting, with APG-5918 receiving an oral presentation.
Genscript Biotech (01548): Legend announced it will present at the American Society of Hematology Annual Meeting.
BrainAurora-B (06681): The first round of the "Brain Star • Healthy Brain Community Tour — National Community Healthy Brain Life Series" themed competition was successfully held, advancing a pilot project for community brain health prevention and intervention.
SHOUCHENG (00697): Its fund invested in Jianzhi, positioning itself around high-quality physical AI data.
KPA-BM HLDGS (02663): Control changed hands, with a mandatory general offer at approximately 13.8% discount; trading resumes on November 5.
Maike Medical-B (02335): Received the first tranche of project funding under a National Science and Technology Major Project and obtained ethics approval from the lead site for the Phase III clinical trial of MT200605.
Hanking Gold (03788): Reported metallurgical test results from recent drilling samples in the historical waste rock dump area of the Rustlers Roost gold deposit.
Hehong Services (06093): Plans to sell 100% equity in Guiyang Xinglong Property Management Co., Ltd. for RMB 115 million.
Federal Pharmaceutical (03933): The marketing registration application for semaglutide injection has been accepted.
GLMS SEC (01456): Guolian Futures plans a share-swap merger with Minsheng Futures.
Shanghai Pharma (02607): Received clinical trial approval notification for treprostinil diethanolamine inhalation powder.
Linmon Media (09857): "Today Is Sun Rain" is scheduled to premiere exclusively on Hunan TV and Mango TV on November 6.
Fosun Pharma (02196): FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria have launched Phase III clinical trials in China.
Honghua Group (00196): A subsidiary signed a drilling rig sales agreement with a Central Asian client, with a total amount of approximately US$59 million.
SBP Group (01177) reached a strategic partnership with Boehringer Ingelheim with a potential total value of US$7 billion.
Henlius (02696): HLX109 injection (an anti-IL1RAP monoclonal antibody) for the treatment of generalized pustular psoriasis has been approved to commence Phase 1 clinical trials in Australia.
Guoxing Aerospace (06935): Subscription period from November 5 to November 10, with listing expected on November 13.
ASMPT (00522): Completed strategic review and will retain the SMT Solutions segment.
CARsgen Therapeutics-B (02171): Abstracts for CT1190B and CT071 will be published at the 2026 ASH Annual Meeting.
HUTCHMED (00013): Announced that sovleplenib has received FDA orphan drug designation for the treatment of autoimmune hemolytic anemia.
Cloudbreak Pharma-B (02592): Topline results from the Phase 3 study of CBT-001 for patients with pterygium.
Grand Pharma (00512): The global innovative ophthalmic drug CBT-001 for pterygium has reached the primary clinical endpoint in an international multicenter Phase III clinical trial.
Operating results:
Autohome-S (02518) released its third-quarter results, with net profit attributable to shareholders of RMB 195 million.
Prudential (02378) reported third-quarter new business profit of US$709 million, up 1%.
Karrie International (01050) issued a positive profit alert, expecting interim profit attributable to shareholders to increase by approximately 100% year-on-year.
Café de Coral Group (00341) issued a positive profit alert, expecting interim profit attributable to shareholders of HK$95.8 million to HK$105 million, an increase of 105% to 125% year-on-year.
Manulife Financial-S (00945) released its third-quarter results, with core earnings of CAD 2.1 billion, up 4% year-on-year.